The novel platinum(IV) prodrug of cisplatin axially conjugated with cannabidiol induces mitochondrial dysfunction and synergistically enhances anti-tumor effects
Journal of Inorganic Biochemistry · 2025
DOI: 10.1016/j.jinorgbio.2025.113003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inorganic Biochemistry, 2025. Verfasst von Rong Lv und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, PR China. Hauptthemen laut MEDLINE: Prodrugs, Cisplatin, Cannabidiol, Mitochondria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Classical cisplatin-based chemotherapeutic drugs are widely used in clinical practice. In recent years, novel platinum-based antitumor drugs have focused on replacing classical cisplatin-like Pt(II) complexes with relatively inert Pt(IV) prodrugs to overcome drug resistance and reduce toxic side effects. Based on the excellent physiological and pharmacological activities of cannabidiol (CBD), this study designed and synthesized novel Pt(IV) prodrugs W1-W6, which are axial conjugates of cisplatin with CBD and specific active small molecules. These prodrugs demonstrated more significant antitumor activity against tested tumor cell lines. Among them, the multifunctional Pt(IV) prodrug W5, conjugated with CBD and the PDK inhibitor DCA, exhibited excellent activity against both platinum-sensitive and cisplatin-resistant tumor strains. The IC50 value of W5 for the A549R tumor strain was 8.53 ± 0.76 μM, significantly higher than that of the cisplatin group and 3.64 times the activity of CBD alone, demonstrating strong synergistic antitumor activity and potential to overcome cisplatin resistance. W5 is reduced by GSH in A549R cells, releasing CBD and Pt(II). Pt(II) binds to DNA, inducing damage and inhibiting repair, while CBD activates pro-apoptotic proteins, leading to mitochondrial dysfunction. Simultaneously, W5 reduces the levels of ROS scavengers, triggering endoplasmic reticulum dysfunction. These three mechanisms synergistically promote tumor cell apoptosis and overcome drug resistance. This design integrates multiple mechanisms through axial functionalization, breaking through the limitation of traditional platinum drugs targeting DNA alone, and achieves synergistic effects by regulating metabolism and intervening in the immune microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, PR China.
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China.
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, PR China. Electronic address: gczasd@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, R., Shi, P., Lu, Z., Wei, T., Yang, J., Liao, X., Yang, B., & Gao, C. (2025). The novel platinum(IV) prodrug of cisplatin axially conjugated with cannabidiol induces mitochondrial dysfunction and synergistically enhances anti-tumor effects. Journal of Inorganic Biochemistry. https://doi.org/10.1016/j.jinorgbio.2025.113003
Vancouver
Lv R, Shi P, Lu Z, Wei T, Yang J, Liao X, et al. The novel platinum(IV) prodrug of cisplatin axially conjugated with cannabidiol induces mitochondrial dysfunction and synergistically enhances anti-tumor effects. Journal of Inorganic Biochemistry. 2025. doi:10.1016/j.jinorgbio.2025.113003
BibTeX
@article{Lv2025,
author = {Lv, Rong and Shi, Pengmin and Lu, Zhiping and Wei, Tangli and Yang, Jing and Liao, Xiali and Yang, Bo and Gao, Chuanzhu},
title = {The novel platinum(IV) prodrug of cisplatin axially conjugated with cannabidiol induces mitochondrial dysfunction and synergistically enhances anti-tumor effects},
journal = {Journal of Inorganic Biochemistry},
year = {2025},
doi = {10.1016/j.jinorgbio.2025.113003}
}
EUVIMED